
    
      The objectives of this study are to measure quality of life, neuropsychological sequelae and
      parental stress before and after gene therapy for ADA-SCID. The population to be studied will
      include up to five patients being treated with gene therapy at the NIH Clinical Center and
      five of their parents. The design of the study will be a non-randomized, longitudinal
      psychometric evaluation. Neuropsychological outcome measures will be the following battery:
      Wechsler Preschool and Primary Scale of Intelligence - Third Edition (WPPSI-III) or the
      Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV); the Wide Range
      Achievement Test - Fourth Edition (WRAT-4); subtests of the NEPSY; The Expressive One Word
      Picture Vocabulary Test (EOWPVT); Grooved Pegboard; Continuous Performance Test (CPT);
      Selective Reminding Test; and the Adaptive Behavior Assessment System- Second Edition.
      Quality of life will be measured with the PedsQL and parental stress will be measured with
      the Parenting Stress Index.
    
  